Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune Gets Closer To Abbott With U.S. Bioscience Merger

Executive Summary

MedImmune's acquisition of U.S. Bioscience will likely lead to a tighter relationship with Abbott. Abbott already co-markets MedImmune's Synagis (palivizumab) and is in the process of acquiring Alza, which co-promotes U.S. Bioscience's top product Ethyol (amifostine) in the U.S.

You may also be interested in...



MedImmune To Add 38 Ethyol Reps Following Product Reacquisition

MedImmune will add 38 oncology reps to promote Ethyol (amifostine) following reacquisition of U.S. rights for the cytoprotective agent from Alza.

MedImmune To Add 38 Ethyol Reps Following Product Reacquisition

MedImmune will add 38 oncology reps to promote Ethyol (amifostine) following reacquisition of U.S. rights for the cytoprotective agent from Alza.

MedImmune Ethyol, Neutrexin sNDA Trials To Be Concluded In 2000

MedImmune expects to complete four Phase III trials in 2000 to gain additional indications for Ethyol and Neutrexin, Executive VP-R&D James Young, PhD, said at a biotechnology press briefing Jan. 6 in Gaithersburg, Md.

Related Content

UsernamePublicRestriction

Register

PS034887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel